Latanoprost Combix

Latanoprost, the active ingredient in Latanoprost Combix, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanoprost Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost Combix belongs to the prostaglandin analog class and is used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. Ocular hypertension: lowers pressure to prevent progression to glaucoma. Elevated intra‑ocular pressure: improves uveoscleral outflow to maintain normal pressure levels.

Latanoprost Combix may cause ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length or thickness - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision shortly after instillation - Mild eye discomfort

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Uveitis or intra‑ocular inflammation - Corneal edema or keratitis - Sudden loss of vision - Persistent ocular pain - Periorbital skin darkening

Before initiating therapy, clinicians should consider several safety aspects.

Monitor intra‑ocular pressure: schedule regular eye examinations to assess efficacy. Assess for ocular infections: avoid use if active conjunctivitis or keratitis is present. Avoid contact lens wear: discontinue lenses during treatment to reduce irritation. Pregnancy and lactation: safety unknown; prescribe only if benefit outweighs potential risk. Drug interactions: inform ophthalmologist of any concurrent ocular medications. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents.

Major Interactions (Avoid): - Concomitant use of other prostaglandin analogs: may increase risk of ocular adverse effects. - Systemic carbonic anhydrase inhibitors: may diminish intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Beta‑blocker eye drops: additive pressure reduction; monitor IOP closely. - Anticholinergic agents: possible reduced efficacy of latanoprost.